Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first participant ...
Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback